Casey L Swanson1, Amanika Kumar1, Joy M Maharaj2, Jennifer L Kemppainen3, Brittany C Thomas3, Megan R Weinhold1, Kristine M Slaby4, Kristin C Mara5, Myra J Wick6, Jamie N Bakkum-Gamez7. 1. Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, United States. 2. Department of Obstetrics and Gynecology, Park Nicollet Methodist Hospital, St. Louis Park, MN, United States. 3. Department of Clinical Genomics, Mayo Clinic, Rochester, MN, United States. 4. Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States. 5. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, United States. 6. Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, United States; Department of Clinical Genomics, Mayo Clinic, Rochester, MN, United States. 7. Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, United States. Electronic address: bakkum.jamie@mayo.edu.
Abstract
OBJECTIVE: To increase genetic counseling referrals for patients with newly diagnosed epithelial ovarian cancer (EOC). METHODS: A practice-gap analysis was performed after measuring baseline genetic counseling referral rates to identify barriers to referral from the multidisciplinary single institution EOC care group. A Genetics Referral Toolkit consisting of a referral template, a genetic risk checklist, family history worksheet and provider and patient awareness was developed to address identified gaps with the goal of increasing referral rates. Clinical characteristics, referral placement, completion of genetic counseling/testing were abstracted for a historic cohort and intervention cohort. Data for the two cohorts were compared using chi-square, Fisher's exact test, or t-test. Association with referral was determined by univariate logistic regression. RESULTS: Eighty one patients from July through December 2013 (historic cohort) and 62 patients from July through December 2015 (intervention cohort) were identified as having a new diagnosis of EOC. Among these women, genetic counseling referral rates increased from 48.1% (39/81) in 2013 to 74.2% (46/62) in 2015 (p=0.002) after implementation of the toolkit. In a subset of patients without a previous genetic counseling referral, 87.9% (29/33) completed counseling and 79.3% (23/29) pursued testing from the historic cohort. In the intervention cohort, 60% (24/40) were seen for counseling and 100% (24/24) had testing. CONCLUSION: Application of a quality improvement process to create a Genetics Referral Toolkit increased the genetic counseling referral rate in patients with a new diagnosis of EOC. The majority of patients who were referred completed genetics consultation and elected genetic testing.
OBJECTIVE: To increase genetic counseling referrals for patients with newly diagnosed epithelial ovarian cancer (EOC). METHODS: A practice-gap analysis was performed after measuring baseline genetic counseling referral rates to identify barriers to referral from the multidisciplinary single institution EOC care group. A Genetics Referral Toolkit consisting of a referral template, a genetic risk checklist, family history worksheet and provider and patient awareness was developed to address identified gaps with the goal of increasing referral rates. Clinical characteristics, referral placement, completion of genetic counseling/testing were abstracted for a historic cohort and intervention cohort. Data for the two cohorts were compared using chi-square, Fisher's exact test, or t-test. Association with referral was determined by univariate logistic regression. RESULTS: Eighty one patients from July through December 2013 (historic cohort) and 62 patients from July through December 2015 (intervention cohort) were identified as having a new diagnosis of EOC. Among these women, genetic counseling referral rates increased from 48.1% (39/81) in 2013 to 74.2% (46/62) in 2015 (p=0.002) after implementation of the toolkit. In a subset of patients without a previous genetic counseling referral, 87.9% (29/33) completed counseling and 79.3% (23/29) pursued testing from the historic cohort. In the intervention cohort, 60% (24/40) were seen for counseling and 100% (24/24) had testing. CONCLUSION: Application of a quality improvement process to create a Genetics Referral Toolkit increased the genetic counseling referral rate in patients with a new diagnosis of EOC. The majority of patients who were referred completed genetics consultation and elected genetic testing.
Authors: Adrianne R Mallen; Claire C Conley; Mary K Townsend; Ali Wells; Bernadette M Boac; Sarah Todd; Anjalika Gandhi; Michelle Kuznicki; Bianca M Augusto; McKenzie McIntyre; Brooke L Fridley; Shelley S Tworoger; Robert M Wenham; Susan T Vadaparampil Journal: Clin Genet Date: 2019-11-24 Impact factor: 4.438
Authors: Christine Garcia; Kara Harrison; Kari L Ring; Mackenzie W Sullivan; Lisa A Rauh; Susan C Modesitt Journal: Fam Cancer Date: 2019-07 Impact factor: 2.375
Authors: Nick Dragojlovic; Kennedy Borle; Nicola Kopac; Ursula Ellis; Patricia Birch; Shelin Adam; Jan M Friedman; Amy Nisselle; Alison M Elliott; Larry D Lynd Journal: Genet Med Date: 2020-06-24 Impact factor: 8.822
Authors: Jenny Lin; Ravi N Sharaf; Rachel Saganty; Danyal Ahsan; Julia Feit; Andrea Khoury; Hannah Bergeron; Eloise Chapman-Davis; Evelyn Cantillo; Kevin Holcomb; Stephanie V Blank; Ying Liu; Charlene Thomas; Paul J Christos; Drew N Wright; Steven Lipkin; Kenneth Offit; Melissa K Frey Journal: Gynecol Oncol Date: 2021-05-19 Impact factor: 5.304
Authors: Brittany A Davidson; Jessie Ehrisman; Shelby D Reed; Jui-Chen Yang; Adam Buchanan; Laura J Havrilesky Journal: Gynecol Oncol Res Pract Date: 2019-01-22
Authors: Janet R Vos; Ingrid E Fakkert; Joanne A de Hullu; Anne M van Altena; Aisha S Sie; Hicham Ouchene; Riki W Willems; Iris D Nagtegaal; Marjolijn C J Jongmans; Arjen R Mensenkamp; Gwendolyn H Woldringh; Johan Bulten; Edward M Leter; C Marleen Kets; Michiel Simons; Marjolijn J L Ligtenberg; Nicoline Hoogerbrugge Journal: J Natl Cancer Inst Date: 2020-02-01 Impact factor: 13.506
Authors: Adrianne R Mallen; Claire C Conley; Lindsay Fuzzell; Dana Ketcher; Bianca M Augusto; McKenzie McIntyre; Laura V Barton; Mary K Townsend; Brooke L Fridley; Shelley S Tworoger; Robert M Wenham; Susan T Vadaparampil Journal: Support Care Cancer Date: 2020-09-25 Impact factor: 3.603